Spots Global Cancer Trial Database for gemcitabine + cisplatin
Every month we try and update this database with for gemcitabine + cisplatin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | NCT04692051 | Biliary Tract C... | Nab-paclitaxel ... Gemcitabine + C... | 18 Years - 70 Years | Huazhong University of Science and Technology | |
| Adjuvant Chemotherapy vs no Chemotherapy for Patients With GallBllader Carcinoma | NCT02778308 | Gallbladder Can... | Gemcitabine + C... | 18 Years - 75 Years | Govind Ballabh Pant Institute of Postgraduate Medical Education and Research | |
| Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) | NCT02453282 | Non-Small-Cell ... | MEDI4736 (Durva... MEDI4736 (Durva... Paclitaxel + Ca... Gemcitabine + C... Gemcitabine + C... Pemetrexed + Ci... Pemetrexed + Ca... Tremelimumab | 18 Years - 130 Years | AstraZeneca | |
| Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC | NCT00254904 | Carcinoma, Non-... | Cisplatin Gemcitabine PF-3512676 Cisplatin Gemcitabine + C... | 18 Years - | Pfizer | |
| Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) | NCT03003962 | Non Small Cell ... | Durvalumab (MED... Paclitaxel + ca... Gemcitabine + c... Gemcitabine + c... Pemetrexed + ci... Pemetrexed + ca... | 18 Years - 130 Years | AstraZeneca | |
| Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC | NCT00254904 | Carcinoma, Non-... | Cisplatin Gemcitabine PF-3512676 Cisplatin Gemcitabine + C... | 18 Years - | Pfizer | |
| Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) | NCT05771480 | Biliary Tract C... | Durvalumab Gemcitabine mon... Gemcitabine + c... Gemcitabine + o... Gemcitabine + c... Gemcitabine + c... Gemcitabine + S... Gemcitabine + c... | 18 Years - 130 Years | AstraZeneca | |
| Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) | NCT02542293 | Non Small Cell ... | Durvalumab +Tre... Paclitaxel + ca... Gemcitabine + c... Gemcitabine + c... Pemetrexed + ci... Pemetrexed + ca... | 18 Years - 130 Years | AstraZeneca | |
| Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer | NCT03403049 | Pancreatic Canc... Cancer | Carbon Ion Gemcitabine + C... Gemcitabine + C... Gemcitabine + E... Gemcitabine Photon | 18 Years - 99 Years | Albert Einstein College of Medicine | |
| Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma | NCT05644743 | Organoids Intrahepatic Ch... | gemcitabine + c... | 18 Years - 80 Years | Eastern Hepatobiliary Surgery Hospital | |
| Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) | NCT02542293 | Non Small Cell ... | Durvalumab +Tre... Paclitaxel + ca... Gemcitabine + c... Gemcitabine + c... Pemetrexed + ci... Pemetrexed + ca... | 18 Years - 130 Years | AstraZeneca | |
| Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer | NCT03403049 | Pancreatic Canc... Cancer | Carbon Ion Gemcitabine + C... Gemcitabine + C... Gemcitabine + E... Gemcitabine Photon | 18 Years - 99 Years | Albert Einstein College of Medicine | |
| Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC | NCT00254904 | Carcinoma, Non-... | Cisplatin Gemcitabine PF-3512676 Cisplatin Gemcitabine + C... | 18 Years - | Pfizer | |
| Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma | NCT05644743 | Organoids Intrahepatic Ch... | gemcitabine + c... | 18 Years - 80 Years | Eastern Hepatobiliary Surgery Hospital | |
| Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC | NCT00254904 | Carcinoma, Non-... | Cisplatin Gemcitabine PF-3512676 Cisplatin Gemcitabine + C... | 18 Years - | Pfizer | |
| Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) | NCT03003962 | Non Small Cell ... | Durvalumab (MED... Paclitaxel + ca... Gemcitabine + c... Gemcitabine + c... Pemetrexed + ci... Pemetrexed + ca... | 18 Years - 130 Years | AstraZeneca | |
| Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) | NCT05771480 | Biliary Tract C... | Durvalumab Gemcitabine mon... Gemcitabine + c... Gemcitabine + o... Gemcitabine + c... Gemcitabine + c... Gemcitabine + S... Gemcitabine + c... | 18 Years - 130 Years | AstraZeneca | |
| A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | NCT04692051 | Biliary Tract C... | Nab-paclitaxel ... Gemcitabine + C... | 18 Years - 70 Years | Huazhong University of Science and Technology |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
